SCHEMBL4485491

SCHEMBL4485491

CCC(CC)c1ccc2nc(-c3ccc(OC)cc3Cl)c(C(N)=O)n2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.40
DBF4 Q9UBU7 2/20 0.40
CCNT1 O60563 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CCNE1 P24864 1/20 0.40
CDK2 P24941 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CDK9 P50750 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CRHR1 P34998 11/20 0.40
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TSPO P30536 1/20 0.36
AKR1C3 P42330 3/20 0.35
AKR1C2 P52895 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483814 0.85 CRHR1 (0.45) CDC7DBF4CCNT1CSNK2A2CCNE1
SCHEMBL4479815 0.84 CRHR1 (0.43) CDC7DBF4CRHR1
SCHEMBL4491735 0.83 CRHR1 (0.44) CRHR1TSPOHSP90AA1HSP90AB1
SCHEMBL4499176 0.76 CRHR1 (0.46) CDC7DBF4CRHR1
SCHEMBL4482511 0.76 CRHR1 (0.46) CDC7DBF4CRHR1
SCHEMBL4498283 0.76 CRHR1 (0.54) CRHR1
SCHEMBL4491763 0.76 CRHR1 (0.45) CDC7DBF4CRHR1
SCHEMBL4486617 0.75 CDC7 (0.47) CDC7DBF4CRHR1KDM4EALDH1A1
SCHEMBL4483117 0.75 CRHR1 (0.44) CDC7DBF4CRHR1
SCHEMBL4479301 0.74 CRHR1 (0.46) CRHR1KDM4ETSPOAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281120-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
EP-1961745-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281120-A1 BICYCLIC HETEROCYCLIC COMPOUND CRHR1, NR3C1, CNR1 CDC7 3697/4885DBF4 2114/4885CCNT1 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.